How many sites should an orthopedic trauma prospective multicenter trial have? A marginal analysis of the Major Extremity Trauma Research Consortium completed trials

Lauren Allen,Robert V. O’Toole,Michael J. Bosse,William T. Obremskey,Kristin R. Archer,Lisa K. Cannada,Jaimie Shores,Lisa M. Reider,Katherine P. Frey,Anthony R. Carlini,Elena D. Staguhn,Renan C. Castillo
DOI: https://doi.org/10.1186/s13063-024-07917-0
IF: 2.728
2024-02-08
Trials
Abstract:Multicenter trials in orthopedic trauma are costly, yet crucial to advance the science behind clinical care. The number of sites is a key cost determinant. Each site has a fixed overhead cost, so more sites cost more to the study. However, more sites can reduce total costs by shortening the study duration. We propose to determine the optimal number of sites based on known costs and predictable site enrollment.
medicine, research & experimental
What problem does this paper attempt to address?